Sami Anttila, MD, PhD

Adjunct Professor in Psychiatry, Medical School, Tampere University, Tampere, Finland

Please note the new email address sami.anttila ( @ ) pp2.inet.fi

Viikki M, Kampman O, Anttila S, Illi A, Setälä-Soikkeli E, Huuhka M, Mononen N, Lehtimäki T, Leinonen E. P2RX7 polymorphisms Gln460Arg and His155Tyr are not associated with major depressive disorder or remission after SSRI or ECT. Neurosci Lett 2011;493(3):127-130.

Viikki M, Anttila S, Kampman O, Illi A, Huuhka M, Setälä-Soikkeli E, Mononen N, Lehtimäki T, Leinonen E. Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. Neurosci Lett  2010;477(3):105-108.

Viikki M, Kampman O, Illi A, Setälä-Soikkeli E, Anttila S, Huuhka M, Nuolivirta T, Poutanen O, Mononen N, Lehtimäki T, Leinonen E. TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. Neurosci Lett 2010;468:80-84.

Anttila S, Viikki M, Huuhka K, Huuhka M, Hietala J, Huhtala H, Rontu R, Lehtimäki T, Leinonen E. TPH2 polymorphisms may modify clinical picture in treatment-resistant depression. Neurosci Lett 2009;464:43-46.

Stewart J, Kampman O, Huuhka M, Anttila S, Huuhka K, Lehtimäki T, Leinonen E. ACE polymorphism and response to electroconvulsive therapy in major depression. Neurosci Lett 2009;458:122-125.

Anttila S, Huuhka M, Hietala J, Huhtala H, Mononen N, Lehtimäki T, Leinonen E. Dopamine 2 receptor C957T and catechol-O-methyltransferase Val158Met polymorphisms are associated with treatment response in electroconvulsive therapy. Neurosci Lett 2008;448:79-83.

Huuhka K, Kampman O, Anttila S, Huuhka M, Rontu R, Mattila KM, Hurme M, Lehtimäki T, Leinonen E. RGS4 polymorphism and response to electroconvulsive therapy in major depressive disorder. Neurosci Lett 2008;437:25-28.

Anttila S, Huuhka K, Huuhka M, Illi A, Rontu R, Leinonen E, Lehtimäki T. Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy. Pharmacogenomics J 2008;8:113-116.

Anttila S, Huuhka K, Huuhka M, Rontu R, Hurme M, Leinonen E, Lehtimäki T. Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. J Neural Transm 2007;114:1065-1068. 

Anttila S, Kampman O, Illi A, Rontu R, Lehtimäki T,  Leinonen E. Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach.  BMC Psychiatry 2007;7:22.

Anttila S, Huuhka K, Huuhka M, Rontu R, Mattila KM, Leinonen E, Lehtimäki T. Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression. J Neural Transm 2007;114:461-468.

Illi A, Kampman O, Hänninen K, Anttila S, Mattila KM, Katila H, Rontu R, Hurme M, Lehtimäki T, Leinonen E. Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia. Hum Psychopharmacol 2007;22:211-215.

Huuhka K, Anttila S, Huuhka M, Leinonen E, Rontu R, Mattila KM, Lehtimäki T. Brain-Derived Neurotrophic Factor (BDNF) polymorphisms G196A and C270T are not associated with the response to electroconvulsive therapy in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 2007;257:31-35.

Hänninen K, Katila H, Anttila S, Rontu R, Maaskola J,  Hurme M, Lehtimäki T. Epidermal growth factor A61G polymorphism is associated with the age of onset of schizophrenia in male patients. J Psychiatr Res 2007;41:8–14.

Kampman O, Illi A, Hänninen K, Katila H, Anttila S, Rontu R, Mattila KM, Leinonen E, Lehtimäki T. RGS4 genotype is not associated with antipsychotic medication response in schizophrenia. J Neural Transm 2006;113:1563-1568.

Hänninen K, Katila H, Kampman O, Anttila S, Illi A, Rontu R, Mattila KM, Hietala J, Hurme M, Leinonen E, Lehtimäki T. Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia. Neurosci Lett 2006;407:195-198.

Anttila S, Illi A, Kampman O, Mattila KM, Lehtimäki T, Leinonen E. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J Neural Transm 2005;112:885-890.

Kampman O, Anttila S, Illi A, Mattila KM, Rontu R, Leinonen E, Lehtimaki T. Interaction of tumor necrosis alpha - G308A and epidermal growth factor gene polymorphisms in early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005;255:279-283. 

Huuhka M, Anttila S, Leinonen E, Huuhka K, Rontu R, Mattila KM, Huhtala H, Lehtimäki T. The apolipoprotein E polymorphism is not associated with response to electroconvulsive therapy in major depressive disorder. J ECT 2005;21:7-11.

Leinonen E, Anttila S, Kampman O, Illi A. Voiko vastetta psyykenlääkkeeseen ennustaa? [Is antipsychotic drug therapy predictable?] Duodecim 2005;121:45-52. (In Finnish)

Kampman O, Anttila S, Illi A, Saarela M, Rontu R, Mattila KM, Leinonen E, Lehtimäki T. Neuregulin genotype and medication response in Finnish patients with schizophrenia. Neuroreport 2004;15:2517-2520.

Anttila S. Genetic factors in schizophrenia. Studies on treatment response to typical neuroleptics and age at onset. Doctoral dissertation. Tampere: 2004. Acta Universitatis Tamperensis 1047. http://www.uta.fi/laitokset/kirjasto/vaitokset/2004/2004094.html 

Anttila S, Illi A, Kampman O, Mattila KM, Lehtimäki T, Leinonen E. Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 2004;14:303-307.

Anttila S, Illi A, Kampman O,  Mattila KM,  Lehtimäki T, Leinonen E. Association of EGF polymorphism with schizophrenia in Finnish men. Neuroreport 2004;15:1215-1218.

Kampman O, Anttila S, Illi A, Mattila KM, Rontu R, Leinonen E, Lehtimäki T. Apolipoprotein E polymorphism is associated with age of onset in schizophrenia. J Hum Genet 2004;49:355-359.

Anttila S, Kampman O, Illi A, Roivas M, Mattila KM, Lassila V, Lehtimäki T, Leinonen E.  NOTCH4 gene promoter polymorphism is associated with the age of onset in schizophrenia. Psychiatr Genet 2003;13:61-64.

Illi A, Kampman O, Anttila S, Roivas M, Mattila KM, Lehtimäki T, Leinonen E. Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. Eur Neuropsychopharmacol 2003;13:147-151.

Illi A, Mattila KM, Kampman O, Anttila S, Roivas M, Lehtimäki T, Leinonen E. Catechol-O-methyltransferase and Monoamine Oxidase A Genotypes and Drug Response to Conventional Neuroleptics in Schizophrenia. J Clin Psychopharmacol 2003;23:429-434.

Kampman O, Anttila S, Illi A, Lehtimäki T, Mattila KM, Roivas M, Leinonen E. Dopamine receptor D2 -141C Insertion/Deletion polymorphism in a Finnish population with schizophrenia. Psychiatry Res 2003;121:89-92.

Anttila S, Leinonen E. Duloxetine Eli Lilly. Curr Opin Investig Drugs 2002;3:1217-1221.

Anttila S, Leinonen E. Psykiatristen sairauksien farmakogenetiikasta. Erikoislääkäri 2002;6:313-6. (In Finnish)

Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001;7:249-64.

Anttila SAK, Räsänen I, Leinonen EV. Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold. Ann Pharmacother 2001;35:1221-1223.

Anttila S, Mattila A, Niskanen P. Klotsapiinin metabolia ja yhteisvaikutukset. Novartis news 1999;1:21-24. (In Finnish)

Anttila S, Mattila A, Niskanen P. Uusien masennuslääkkeiden yhteisvaikutukset muiden psyykenlääkkeiden kanssa. Suomen Lääkärilehti 1999;1-2:39-44. (In Finnish)

Anttila SAK, Leinonen EVJ, Seppälä JA. Delirium during clarithromycin treatment: A case report. Nordic Journal of Psychiatry 1999;2:139-140.